Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease

References

• Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–361.
   PubMed Web of Science ®Google Scholar
• Ruemmele F, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179–1207.
   PubMed Web of Science ®Google Scholar
• Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care – an evidence-based guideline from European Crohn’s and Colitis Organization and uropean Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257–291.
   PubMed Web of Science ®Google Scholar
• van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020:jjaa161.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Waterman M, Turner D, ESPGHAN Paediatric IBD Porto Group, et al. Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN paediatric IBD Porto group. J Pediatr Gastroenterol Nutr. 2015;61(4):503–508.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Assa A, Bronsky J, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the pediatric IBD porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68(1):144–153.
   PubMed Web of Science ®Google Scholar
• Nikkonen A, Kolho KL. Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatr. 2020;109(4):836–841.
   PubMed Web of Science ®Google Scholar
• Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019;20(10):2529.
   Web of Science ®Google Scholar
• Winter DA, Joosse ME, de Wildt SN, et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr. 2020;70(6):763–776.
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Piester TL, Park KT. Infliximab dosing strategies and predicted trough exposure in children with crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(5):723–727.
   PubMed Web of Science ®Google Scholar
• Merras-Salmio L, Kolho KL. Clinical use of infliximab trough levels and antibodies to infliximab in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(2):272–278.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14(3):353–358.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis. 2009;15:816–822.
   PubMed Web of Science ®Google Scholar
• De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited. Aliment Pharmacol Ther. 2011;33(2):243–250.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Sipponen T. The long-term outcome of anti-TNF-alpha therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2014;49(4):434–441.
   PubMed Web of Science ®Google Scholar
• Kolho KL. Therapeutic drug monitoring and outcome of infliximab therapy in pediatric onset inflammatory bowel disease. Front Pediatr. 2020;8:623689.
   PubMed Web of Science ®Google Scholar
• Puolanne AM, Kolho KL, Alfthan H, et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3123–3130.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41(6):720–725.
   PubMed Web of Science ®Google Scholar
• Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease decreases fecal calprotectin levels. WJG. 2011;17(47):5166–5171.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(1):74–80.
   PubMed Web of Science ®Google Scholar
• Haapamäki J, Roine RP, Sintonen H, et al. Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health. 2011;47(11):832–837.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Privitera AC, et al. A propensity score-matched comparison of infliximab and adalimumab in tumour necrosis factor-α inhibitor-naïve and non-naïve patients with Crohn’s disease: real-life data from the sicilian network for inflammatory bowel disease. J Crohns Colitis. 2019;13(2):209–217.
   PubMed Web of Science ®Google Scholar
• Aloi M, Bramuzzo M, Arrigo S, et al. Efficacy and safety of adalimumab in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD registry. J Pediatr Gastroenterol Nutr. 2018;66(6):920–925.
   PubMed Web of Science ®Google Scholar
• Alvisi P, Arrigo S, Cucchiara S, et al. Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. Biologics. 2019;13:13–21.
   PubMed Web of Science ®Google Scholar
• Holmstrøm RB, Mogensen DV, Brynskov J, et al. Interactions between thiopurine metabolites, adalimumab, and antibodies against adalimumab in previously infliximab-treated patients with inflammatory bowel disease. Dig Dis Sci. 2018;63(6):1583–1591.
   PubMed Web of Science ®Google Scholar
• Meredith J, Henderson P, Wilson DC, et al. Withdrawal of combination immunotherapy in paediatric inflammatory bowel Disease – an international survey of practice. J Pediatr Gastroenterol Nutr. 2021. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Weinstein-Nakar I, Focht G, Church P, et al. Associations among mucosal and transmural healing and fecal level of calprotectin in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16(7):1089–1097.e4.
   PubMed Web of Science ®Google Scholar
• Scarallo L, Alvisi P, Bolasco G, et al. Mucosal and histologic healing in children with inflammatory bowel disease treated with antitumor necrosis factor-alpha. J Pediatr Gastroenterol Nutr. 2021;72(5):728–735.
   PubMed Web of Science ®Google Scholar
• Ungar B, Ben-Shatach Z, Selinger L, et al. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn’s disease. United European Gastroenterol J. 2020;8(2):167–174.
   PubMed Web of Science ®Google Scholar
• Salvador-Martín S, Kaczmarczyk B, Álvarez R, et al. Whole transcription profile of responders to anti-TNF drugs in pediatric inflammatory bowel disease. Pharmaceutics. 2021;13(1):77.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110(6):921–930.
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis. 2016;10(8):943–952.
   PubMed Web of Science ®Google Scholar
• Estevinho MM, Rocha C, Correia L, et al. Features of fecal and colon microbiomes associate with responses to biologic therapies for inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol. 2020;18(5):1054–1069.
   PubMed Web of Science ®Google Scholar
• Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–1321.
   PubMed Web of Science ®Google Scholar